Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial
Nicotine and Tobacco Research · 2025
DOI: 10.1093/ntr/ntae079 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Brittney Keller-Hamilton und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: Nicotine, Tobacco Use Disorder, Tobacco Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, The Ohio State University Comprehensive Cancer Center-The James, NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Many oral nicotine pouch (ONP) brands use synthetic nicotine, which typically contains a racemic (50:50) mixture of nicotine’s two stereoisomers: S-nicotine and R-nicotine. Because tobacco-derived nicotine contains more than 99% S-nicotine, the effects of R-nicotine in humans are not well known. We compared systemic nicotine exposure and product appeal of ONPs containing more than 99% S-nicotine versus racemic nicotine. Aims and Methods N = 18 adult smokers (Mage = 45 years, 66.7% male, 77.8% White) enrolled in a three-visit single-blind, randomized crossover study. During each visit, participants used one wintergreen-flavored, 3 mg nicotine ONP for 30 min following at least12 h nicotine abstinence. Study ONP #1 contained more than 99% S-nicotine and the other two study ONPs contained racemic nicotine (collapsed for analyses). Plasma nicotine assessments and measures of withdrawal relief occurred at t = 0, 5, 15, 30, 60, and 90 min; measures of product appeal were assessed following ONP use.
Results
Using the ONP with more than 99% S-nicotine resulted in greater plasma nicotine concentration from 15 to 90 min (p < .0001) and greater maximum plasma nicotine concentration than the ONPs with racemic nicotine (M = 9.9 ng/mL [SD = 2.5] vs. M = 5.7 ng/mL [SD = 2.8], respectively; p < .0001). Product liking and withdrawal relief were similar across ONPs, although participants reported more “bad effects” when using the ONP with more than 99% S-nicotine.
Conclusions
Participants reported few subjective differences in ONPs according to nicotine stereoisomer, but plasma nicotine concentration was greater for ONPs using more than 99% S-nicotine. ONPs with more than 99% S-nicotine (vs. racemic nicotine) might be better substitutes for cigarettes, but research into other ONP characteristics (eg flavors, freebase nicotine) is needed to inform regulation.
Implications
Little is known about the effects of racemic (vs. S-) nicotine in humans. In a sample of adults who smoke cigarettes, we identified that oral nicotine pouches containing racemic nicotine exposed participants to less nicotine than oral nicotine pouches containing only S-nicotine, but both types of oral nicotine pouches held similar, moderate appeal. Additional research evaluating the roles that flavorings, total nicotine concentration, and freebase nicotine play in the abuse liability of oral nicotine pouches would inform comprehensive product regulations to support public health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
- Comprehensive Cancer Center, Center for Tobacco Research, The Ohio State University, Columbus, OH, USA.
- College of Public Health, The Ohio State University, Columbus, OH, USA.
ORCID-Profile: Brittney Keller-Hamilton, Ahmad El-Hellani, Darren Mays
Förderung
- NIDA NIH HHS
- The Ohio State University Comprehensive Cancer Center-The James
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
- The Ohio State University Comprehensive Cancer Center—The James
- National Institute on Drug Abuse
- National Cancer Institute
Zitieren
APA
Keller-Hamilton, B., Curran, H., Alalwan, M., Hinton, A., Brinkman, M. C., El-Hellani, A., Wagener, T. L., Chrzan, K., Atkinson, L., Suraapaneni, S., & Mays, D. (2025). Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae079
Vancouver
Keller-Hamilton B, Curran H, Alalwan M, Hinton A, Brinkman MC, El-Hellani A, et al. Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntae079
BibTeX
@article{KellerHamilton2025,
author = {Keller-Hamilton, Brittney and Curran, Hayley and Alalwan, Mahmood and Hinton, Alice and Brinkman, Marielle C and El-Hellani, Ahmad and Wagener, Theodore L and Chrzan, Kirsten and Atkinson, Leanne and Suraapaneni, Sriya and Mays, Darren},
title = {Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial},
journal = {Nicotine and Tobacco Research},
year = {2025},
doi = {10.1093/ntr/ntae079}
}
EUVIMED